Is Adjusting Dosing The Right Approach for Frail Myeloma Patients? | Charlotte Pawlyn, PhD

Maintenance Strategies Post-ASCT for High-Risk Newly Diagnosed Myeloma | Arvind Suresh, MD

Targeting t(4; 14) Myeloma with a New Oral MMSET Inhibitor | Saad Usmani, MD

Fewer Injections, Same-Day Collection: A New Option Before Transplant | Jack Khouri, MD

Sonrotoclax Combo Shows Promise for 11;14 Myeloma | Hang Quach, MD

How Doctors Spot Hidden Myeloma Risks Early | Bruno Paiva, PhD

MagnetisMM‑3: Pausing Elranatamab Without Losing Response | Alexander Lesokhin, MD

Reduced Cardiac Risk Factors in AL Amyloidosis with D-VCd | Vaishali Sanchorawala, MD

Myeloma Bispecific Antibodies in the Real World: Practical Insights | Sikander Ailawadhi, MD

CAR-T Dosing Matters: Real-World Data on Effectiveness and Outcomes | Ran Reshef, MD

Duffy Null: A Breakthrough for Biomarkers in AA Myeloma Patients | Paul Richardson, MD

Can AI Help Detect Myeloma Earlier? New Insights | Faith Davies, MD

Myeloma Treatment At Home? On-body Injector System for Isatuximab | Sikander Ailawadhi, MD

Using Sequencing to Measure MRD in the Peripheral Blood | Dory Abelman, PhD | #ASH25

DREAMM-8 Study- Blenrep in Myeloma | Paul Richardson, MD

Is Earlier CAR-T the Key to Longer Myeloma Control? | Samir Parekh, MBB

Relapsed & Refractory Myeloma: What’s Changing and What’s Next Rahul Banerjee, MD, FACP

Revolutionizing Myeloma Treatment: BCMA/CD19 Dual CAR-T Explained | Shambavi Richard, MD

STOMP Trial - Selinexor + Mezigdomide + Dex in Relapsed Myeloma | Paul Richardson, MD

LimiTEC: Limited-Duration Teclistamab Results | Beatrice Razzo, MD & Cindy Chmielewski

Late-Breaking Abstracts:Faster In Vivo CAR-T Cells & Earlier Bispecifics | Faith Davies, MD

Belantamab: Lowering Administration Burden for Myeloma Patients | Attaya Suvannasankha, MD